MedKoo Cat#: 563164 | Name: TZ9
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TZ9 is an inhibitor of Rad6B expressing human breast cancer cell lines MDA-MB-231 and MCF-7. It is also the first competitive E2-ligase inhibitor that acts by blocking thioester formation.

Chemical Structure

TZ9
TZ9
CAS#1002789-86-7

Theoretical Analysis

MedKoo Cat#: 563164

Name: TZ9

CAS#: 1002789-86-7

Chemical Formula: C17H14N6O4

Exact Mass: 366.1077

Molecular Weight: 366.33

Elemental Analysis: C, 55.74; H, 3.85; N, 22.94; O, 17.47

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
1g USD 4,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
TZ9; TZ-9; TZ 9; SMI#9;
IUPAC/Chemical Name
(4-Amino-6-anilino-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
InChi Key
RRRDZFQRNJTKHL-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H14N6O4/c18-16-20-14(21-17(22-16)19-12-4-2-1-3-5-12)10-27-15(24)11-6-8-13(9-7-11)23(25)26/h1-9H,10H2,(H3,18,19,20,21,22)
SMILES Code
O=C(OCC1=NC(N)=NC(NC2=CC=CC=C2)=N1)C3=CC=C([N+]([O-])=O)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 366.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nethi SK, P NAA, Rico-Oller B, Rodríguez-Diéguez A, Gómez-Ruiz S, Patra CR. Design, synthesis and characterization of doped-titanium oxide nanomaterials with environmental and angiogenic applications. Sci Total Environ. 2017 Dec 1;599-600:1263-1274. doi: 10.1016/j.scitotenv.2017.05.005. Epub 2017 May 15. PubMed PMID: 28525935. 2: Kothayer H, Spencer SM, Tripathi K, Westwell AD, Palle K. Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. Bioorg Med Chem Lett. 2016 Apr 15;26(8):2030-4. doi: 10.1016/j.bmcl.2016.02.085. Epub 2016 Mar 2. PubMed PMID: 26965855; PubMed Central PMCID: PMC4808444. 3: Kothayer H, Elshanawani AA, Abu Kull ME, El-Sabbagh OI, Shekhar MP, Brancale A, Jones AT, Westwell AD. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6886-9. doi: 10.1016/j.bmcl.2013.09.087. Epub 2013 Oct 6. PubMed PMID: 24153206.